Trexquant Investment LP bought a new position in shares of Catalent, Inc. (NYSE:CTLT) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 6,449 shares of the company’s stock, valued at approximately $257,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. State of Wisconsin Investment Board bought a new stake in shares of Catalent in the second quarter worth $3,334,000. 361 Capital LLC grew its stake in shares of Catalent by 18.6% in the third quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock worth $2,795,000 after purchasing an additional 10,974 shares during the last quarter. Chicago Equity Partners LLC grew its stake in shares of Catalent by 20.4% in the second quarter. Chicago Equity Partners LLC now owns 109,825 shares of the company’s stock worth $3,855,000 after purchasing an additional 18,600 shares during the last quarter. Airain ltd bought a new stake in shares of Catalent in the second quarter worth $3,524,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Catalent in the second quarter worth $23,092,000. 99.49% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Catalent, Inc. (NYSE CTLT) opened at $39.34 on Friday. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. The company has a market cap of $5,212.08, a price-to-earnings ratio of 27.43, a price-to-earnings-growth ratio of 2.52 and a beta of 1.41. Catalent, Inc. has a 1 year low of $23.41 and a 1 year high of $43.39.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.16 earnings per share. equities research analysts expect that Catalent, Inc. will post 1.46 EPS for the current fiscal year.
Several brokerages recently weighed in on CTLT. BidaskClub raised shares of Catalent from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Wells Fargo & Company boosted their price objective on shares of Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 20th. Bank of America reissued a “buy” rating and issued a $45.00 price objective (up previously from $40.00) on shares of Catalent in a research note on Wednesday, September 20th. Piper Jaffray Companies reissued a “buy” rating and issued a $45.00 price objective on shares of Catalent in a research note on Tuesday, August 29th. Finally, Jefferies Group reissued a “hold” rating and issued a $38.00 price objective (up previously from $35.00) on shares of Catalent in a research note on Tuesday, August 29th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.25.
In other news, Director Uwe Roehrhoff purchased 7,500 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were acquired at an average price of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.70% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.